<html>
        <head>
            <link rel="stylesheet" type="text/css" href="layout.css" />
        </head>
        <style> 
            .right { 
                margin-left: 160px;
            } 
        </style>
        
        <div class="sidenav">
            <a href="#">About</a>
            <a href="index_gpt.html">Index</a>
        </div>
    <div class="header"><h3>MADIT-CRT</h3></div><p><span class="main">"Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events". </span></p><p><span class="contents">
                                        Links to original sources:
                                        <a href=https://www.wikijournalclub.org//wiki/MADIT-CRT>Wiki Journal Post</a>
                                        <a href=http://www.nejm.org/doi/full/10.1056/NEJMoa0906431>Full Journal Article</a>
                                        </span></p><p><span class="main">The New England Journal of Medicine. 2009. 361(14):1329-1338.
PubMed•Full text•PDF
 </span></p><p><span class="main">Contents
1 Clinical Question
2 Bottom Line
3 Major Points
4 Guidelines
5 Design
6 Population
6.1 Inclusion Criteria
6.2 Exclusion Criteria
6.3 Baseline Characteristics
7 Interventions
8 Outcomes
8.1 Primary Outcome
8.2 Secondary Outcomes
9 Funding
10 Further Reading
 </span></p><h2><span class="labels">Clinical Question</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Does cardiac-resynchronization therapy (CRT) with biventricular pacing reduce the risk of death or heart-failure events in patients with mild cardiac symptoms, a reduced ejection fraction, and a wide QRS complex?
 </span></p><h2><span class="labels">Bottom Line</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">CRT combined with an implantable cardioverter–defibrillator (ICD) decreased the risk of heart-failure events in relatively asymptomatic patients with a low ejection fraction and wide QRS complex.
 </span></p><h2><span class="labels">Major Points</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">CRT has demonstrated benefits in reducing symptoms, hospitalization rates, and mortality in patients with advanced heart failure. The MADIT-CRT trial showed that CRT, when combined with ICD therapy, reduces the risk of death or nonfatal heart-failure events in patients with mild heart failure symptoms, reduced ejection fraction, wide QRS complex, and sinus rhythm.
 </span></p><h2><span class="labels">Guidelines</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">The 2008 guidelines for implantation of cardiac devices recommend CRT as a class I indication for patients with a left ventricular ejection fraction of 35% or less, a QRS duration of 120 msec or more, and sinus rhythm who have NYHA functional class III or ambulatory class IV heart-failure symptoms.
 </span></p><h2><span class="labels">Design</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Multicenter, randomized, controlled trial
N=1,820
CRT-ICD (n=1,089)
ICD alone (n=731)
Setting: 110 hospital centers
Enrollment: 2004-2008
Mean follow-up: 2.4 years
Analysis: Intention-to-treat
Primary outcome: Death from any cause or a nonfatal heart-failure event
 </span></p><h2><span class="labels">Population</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Inclusion Criteria: NYHA class I (ischemic cardiomyopathy) or class II (ischemic or nonischemic cardiomyopathy), ejection fraction of ≤30%, QRS duration ≥130 msec, sinus rhythm.
Exclusion Criteria: Existing or planned CRT, recent MI or cardiac intervention, atrial fibrillation, and other criteria.
Baseline Characteristics: Similar across groups.
 </span></p><h2><span class="labels">Interventions</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Patients were randomly assigned to receive CRT with an ICD (CRT-ICD group) or an ICD alone (ICD-only group).
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Primary Outcome: Risk reduction of 34% for death or nonfatal heart-failure events in the CRT-ICD group compared to the ICD-only group (hazard ratio, 0.66; 95% confidence interval, 0.52 to 0.84; P=0.001).
Secondary Outcomes: Significant reduction in left ventricular volumes and improvement in ejection fraction in the CRT-ICD group.
 </span></p><h2><span class="labels">Funding</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Supported by a research grant from Boston Scientific to the University of Rochester.
 </span></p><h2><span class="labels">Further Reading</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Full text available on the New England Journal of Medicine website. </span></p>    	
        <div class="footer">Footer</div>
        </body>
        </html>